Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Taking into account the excellent prognosis of patients with HPV-positive oropharyngeal
cancer with < 10 pack-year smoking, the investigators hypothesize that reducing the intensity
of therapy for these patients will reduce treatment sequelae, notably long-term dysphagia,
without affecting their cure rates. The main Aim is to assess whether reducing treatment
intensity, by replacing concurrent chemotherapy with cetuximab, will indeed achieve improved
long-term toxicity.
The primary objectives include the following: to confirm that reducing treatment intensity in
patients with HPV-related oropharyngeal cancer and < 10 pack-year smoking history by
replacing concurrent chemotherapy with concurrent cetuximab, does not significantly increase
the proportion of patients whose tumors recur, compared to our previous experience in similar
patients receiving chemo-RT and to compare the toxicity in patients receiving cetuximab-RT to
similar patients treated with 7 weeks of chemotherapy concurrent with RT ("standard therapy")
in UMCC 2-21.
Phase:
N/A
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center